Chand, UmeshPriyambada, PragnyaKushawaha, Pramod Kumar2024-01-212024-08-132024-01-212024-08-132023-03-13944501310.1016/j.micres.2023.127362http://10.2.3.109/handle/32116/3481Staphylococcus aureus (S. aureus) is a leading and crucial infectious threat to global public health due to the widespread emergence of antibiotic-resistant strains such as Methicillin-Resistant S. aureus (MRSA). MRSA infects immunocompromised patients and healthy individuals and has rapidly spread from the healthcare setting to the outside community. The development of flawless vaccines become a medical need worldwide against multi-drug resistant S. aureus. Therefore, protection by an immune-based strategy may provide valuable measures to contain the spread of invasive S. aureus infections. Several vaccine candidates have been prepared which are either in the preclinical phase or in the early clinical phase, whereas several candidates have failed to show a protective efficacy in human subjects. Currently, research is focusing on identifying novel vaccine formulations able to elicit potent humoral and cellular immune responses. Several approaches have also been made to the development of monoclonal or polyclonal antibodies for passive immunization to protect against S. aureus infections. In recent years, a multi-epitope vaccine has emerged as a novel platform for subunit vaccine design by using computational approaches. Therefore, in this review, we have summarized and discussed the mechanistic overview of different strategies used to develop potential vaccine candidates and passive interventions which are in different stages of clinical trials to fight multi-drug resistant S. aureus infections. � 2023 Elsevier GmbHen-USClinical trialsHumoral and cellular immune responsesMonoclonal/polyclonal antibodiesPassive immunizationStaphylococcus aureusVaccineReviewhttps://linkinghub.elsevier.com/retrieve/pii/S0944501323000642